Nicolas De Leiris1,2, Berangère Ruel3, Jean Vervandier1, José Boucraut4, Stephan Grimaldi5, Tatiana Horowitz6, Jean Pelletier3, Frederique Fluchere5, Jacques-Yves Campion6, Elsa Kaphan3, Eric Guedj7. 1. Nuclear Medicine Department, Grenoble Alpes University Hospital, Grenoble, France. 2. Laboratoire Radiopharmaceutiques Biocliniques, INSERM, Univ. Grenoble Alpes, 38000, Grenoble, France. 3. Service de Neurologie, Hôpital de La Timone, Pôle de Neurosciences Cliniques, Aix Marseille Univ, APHM, 13005, Marseille, France. 4. Immunology Laboratory, INT, CNRS, AP-HM, Aix Marseille University, Marseille, France. 5. Department of Neurology and Movement Disorders, CHU Timone, APHM, Aix-Marseille Univ, 13385 Cedex 05, Marseille, France. 6. APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix Marseille Univ, Marseille, France. 7. APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix Marseille Univ, Marseille, France. eric.guedj@ap-hm.fr.
Abstract
PURPOSE: The aim of this [18F]-FDG PET study was to determine the diagnostic value of the cortex/striatum metabolic ratio in a large cohort of patients suffering from autoimmune encephalitis (AE) and to search for correlations with the course of the disease. METHODS: We retrospectively collected clinical and paraclinical data of patients with AE, including brain 18F-FDG PET/CT. Whole-brain statistical analysis was performed using SPM8 software after activity parametrization to the striatum in comparison to healthy subjects. The discriminative performance of this metabolic ratio was evaluated in patients with AE using receiver operating characteristic curves against 44 healthy subjects and a control group of 688 patients with MCI. Relationship between cortex/striatum metabolic ratios and clinical/paraclinical data was assessed using univariate and multivariate analysis in patients with AE. RESULTS: Fifty-six patients with AE were included. In comparison to healthy subjects, voxel-based statistical analysis identified one large cluster (p-cluster < 0.05, FWE corrected) of widespread decreased cortex/striatum ratio in patients with AE. The mean metabolic ratio was significantly lower for AE patients (1.16 ± 0.13) than that for healthy subjects (1.39 ± 0.08; p < 0.001) and than that for MCI patients (1.32 ± 0.11; p < 0.001). A ratio threshold of 1.23 allowed to detect AE patients with a sensitivity of 71% and a specificity of 82% against MCI patients, and 98% against healthy subjects. A lower cortex/striatum metabolic ratio had a trend towards shorter delay before 18F-FDG PET/CT (p = 0.07) in multivariate analysis. CONCLUSION: The decrease in the cortex/striatal metabolic ratio has a good early diagnostic performance for the differentiation of AE patients from controls.
PURPOSE: The aim of this [18F]-FDG PET study was to determine the diagnostic value of the cortex/striatum metabolic ratio in a large cohort of patients suffering from autoimmune encephalitis (AE) and to search for correlations with the course of the disease. METHODS: We retrospectively collected clinical and paraclinical data of patients with AE, including brain 18F-FDG PET/CT. Whole-brain statistical analysis was performed using SPM8 software after activity parametrization to the striatum in comparison to healthy subjects. The discriminative performance of this metabolic ratio was evaluated in patients with AE using receiver operating characteristic curves against 44 healthy subjects and a control group of 688 patients with MCI. Relationship between cortex/striatum metabolic ratios and clinical/paraclinical data was assessed using univariate and multivariate analysis in patients with AE. RESULTS: Fifty-six patients with AE were included. In comparison to healthy subjects, voxel-based statistical analysis identified one large cluster (p-cluster < 0.05, FWE corrected) of widespread decreased cortex/striatum ratio in patients with AE. The mean metabolic ratio was significantly lower for AE patients (1.16 ± 0.13) than that for healthy subjects (1.39 ± 0.08; p < 0.001) and than that for MCI patients (1.32 ± 0.11; p < 0.001). A ratio threshold of 1.23 allowed to detect AE patients with a sensitivity of 71% and a specificity of 82% against MCI patients, and 98% against healthy subjects. A lower cortex/striatum metabolic ratio had a trend towards shorter delay before 18F-FDG PET/CT (p = 0.07) in multivariate analysis. CONCLUSION: The decrease in the cortex/striatal metabolic ratio has a good early diagnostic performance for the differentiation of AE patients from controls.
Authors: Divyanshu Dubey; Sean J Pittock; Cecilia R Kelly; Andrew McKeon; Alfonso Sebastian Lopez-Chiriboga; Vanda A Lennon; Avi Gadoth; Carin Y Smith; Sandra C Bryant; Christopher J Klein; Allen J Aksamit; Michel Toledano; Bradley F Boeve; Jan-Mendelt Tillema; Eoin P Flanagan Journal: Ann Neurol Date: 2018-01 Impact factor: 10.422
Authors: Julien Hébert; Priti Gros; Sarah Lapointe; Fatima S Amtashar; Claude Steriade; Catherine Maurice; Richard A Wennberg; Gregory S Day; David F Tang-Wai Journal: J Neuroimmunol Date: 2020-06-05 Impact factor: 3.478
Authors: Beau M Ances; Roberta Vitaliani; Robert A Taylor; David S Liebeskind; Alfredo Voloschin; David J Houghton; Steven L Galetta; Marc Dichter; Abass Alavi; Myrna R Rosenfeld; Josep Dalmau Journal: Brain Date: 2005-05-11 Impact factor: 13.501
Authors: F Ducray; G Demarquay; F Graus; E Decullier; J-C Antoine; B Giometto; D Psimaras; J-Y Delattre; A F Carpentier; J Honnorat Journal: Eur J Neurol Date: 2014-01-28 Impact factor: 6.089
Authors: Julien Hébert; Gregory S Day; Claude Steriade; Richard A Wennberg; David F Tang-Wai Journal: Can J Neurol Sci Date: 2018-06-25 Impact factor: 2.104
Authors: Francesc Graus; Maarten J Titulaer; Ramani Balu; Susanne Benseler; Christian G Bien; Tania Cellucci; Irene Cortese; Russell C Dale; Jeffrey M Gelfand; Michael Geschwind; Carol A Glaser; Jerome Honnorat; Romana Höftberger; Takahiro Iizuka; Sarosh R Irani; Eric Lancaster; Frank Leypoldt; Harald Prüss; Alexander Rae-Grant; Markus Reindl; Myrna R Rosenfeld; Kevin Rostásy; Albert Saiz; Arun Venkatesan; Angela Vincent; Klaus-Peter Wandinger; Patrick Waters; Josep Dalmau Journal: Lancet Neurol Date: 2016-02-20 Impact factor: 44.182